SLV213

DRUG2 trials

Sponsors

Kenneth Krantz, MD, PhD, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19Covid19

Phase 1

Safety Study of SLV213 for the Treatment of COVID-19.

TerminatedNCT06146374

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2024-04-09End: 2024-07-08Updated: 2025-07-22

Phase 2

SLV213 Treatment in Ambulatory COVID-19 Patients

Kenneth Krantz, MD, PhDCovid19

Start: 2023-11-01End: 2024-07-01Target: 81Updated: 2023-04-12